
|Videos|April 13, 2016
Sarah B. Goldberg on New Immunotherapy Options for Patients With Lung Cancer
Author(s)Sarah B. Goldberg, MD, MPH
Sarah B. Goldberg, MD, MPH, assistant professor of medicine at Yale Cancer Center, discusses new treatment options for patients with non-small cell lung cancer (NSCLC).
Advertisement
Sarah B. Goldberg, MD, MPH, assistant professor of medicine at Yale Cancer Center, discusses new treatment options for patients with non-small cell lung cancer (NSCLC).
The FDA has approved two immunotherapy agents for NSCLC, nivolumab (Opdivo) and pembrolizumab (Keytruda) as an option for patients who already received one line of chemotherapy that did not work. These two agents work by blocking the PD-1 pathway, which lets the patient's immune system attack the cancer.
Newsletter
Knowledge is power. Don’t miss the most recent breakthroughs in cancer care.
Advertisement
Advertisement
Advertisement
Trending on Oncology Nursing News
1
FDA Approves TTFields Device With Chemo in Pancreatic Cancer
2
Understanding the Pembrolizumab Treatment Combo in Platinum-Resistant Ovarian Cancers
3
Advancing NSCLC Care: RMAT Status, Treatment Timing, and ASCO Updates
4
FDA Approves Pembrolizumab Combination in Platinum-Resistant Ovarian Cancer
5



































